InvestorsHub Logo
Followers 120
Posts 20269
Boards Moderated 0
Alias Born 06/13/2011

Re: Atom0aks post# 214653

Monday, 09/16/2019 5:02:24 PM

Monday, September 16, 2019 5:02:24 PM

Post# of 424170
Atom , Sharin et al ... Vascepa is not in the 2019 Kaiser formulary ...updated 8/6/19.

Neither is Repatha ...which required a special authorization letter from my Cardio , to be covered under my Kaiser plan.

The NLA statement is pretty clear ...Class 1 recommendation for clinical ASCVD with TG's 135-499 on optimal statin therapy ...plus diabetics etc .
NLA does not state that Vascepa is only for secondary prevention.

Theres a Kaiser Formulary committee that meets fairly regularly ...I need to find a way to get them to reassess their position on Vascepa .
Any suggestions would be welcome
Kiwi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News